Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.

Urologic oncology - 1 Jan 2000

Jaboin Jerry J, Hwang Misun, Perez Carmen A, Cooper Calvin, Chen Heidi, Ye Chuanzhong, Cai Qiuyin, Wills Marcia L, Lu Bo

Abstract excerpt

OBJECTIVES: Mouse double-minute 2 (MDM2) SNP309 polymorphism (T>G) has been correlated with an increased risk of cancer in multiple tumor types. MDM2 overexpression has shown to be weakly associated with distant tumor metastases, and down-regulation of MDM2 via antisense oligonucleotides in vitro has resulted in the radiosensitization of prostate cancer cell lines. Based on these results, we decided to evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Prognosis

Share to Prostatectomy

Share to Prostatic Neoplasms

Share to Proto-Oncogene Proteins c-mdm2

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 19523862
DOI: 10.1016/j.urolonc.2009.03.031
PMCID: PMC3782416

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.PMID 19523862Read ↗

Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.Semantic proximity Read ↗

Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis.Semantic proximity Read ↗

Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk.Semantic proximity Read ↗

The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.Semantic proximity Read ↗

The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.Semantic proximity Read ↗

Association of MDM2 T309G (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population.Semantic proximity Read ↗

Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.Semantic proximity Read ↗

Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.Semantic proximity Read ↗

MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.Semantic proximity Read ↗

The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer.Semantic proximity Read ↗

Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.Semantic proximity Read ↗

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.